Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer
AssigneeAstraZeneca AB
InventorsBernard Christophe Barlaam, Kurt Gordon Pike
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstraZeneca AB
InventorsBernard Christophe Barlaam, Kurt Gordon Pike
Estimating the term…
The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.
A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[5,4-c]quinolin-2-one, having the structure:
A compound, wherein the compound is 8-[6-(3-dimethylaminopropoxy)pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazol 5,4-c]quinolin-2-one, having the structure:
Dependencies are inferred from the claim text.